DaVita Statement on GLP-1 And Potential Implications On Chronic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
DaVita Inc. has issued a statement in response to Novo Nordisk's FLOW study on Ozempic, a drug for type 2 diabetes, which aims to show that it delays the progression of chronic kidney disease (CKD) and lowers the risk of kidney and cardiovascular mortality. DaVita's chief medical officer, Dr. Jeff Giullian, stated that while it's too early to draw conclusions from the study, they believe its findings may have limited application to the overall CKD patient population. Novo Nordisk plans to release the FLOW study in the first half of 2024.
October 12, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
DaVita's response to Novo Nordisk's FLOW study indicates cautious optimism. The company is closely monitoring the developments and potential benefits of GLP-1s for kidney disease patients. However, they believe the study's findings may have limited application to the overall CKD patient population.
DaVita's response to the FLOW study indicates that they are closely monitoring the developments and potential benefits of GLP-1s for kidney disease patients. However, they believe that the study's findings may have limited application to the overall CKD patient population, which could potentially limit the impact of the study on DaVita's operations and patient care strategies.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100